Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Total revenue $ 3,220 $ 4,141
Operating expenses:    
Research and development 21,368 20,631
General and administrative 8,181 5,647
Total operating expenses 29,549 26,278
Loss from operations 26,329 22,137
Interest and other income, net 52 472
Interest and other expense, net (501) (348)
Loss before provision for income taxes 26,778 22,013
Provision for income taxes 0 5
Net loss 26,778 22,018
Net loss attributable to common shareholders $ 26,778 $ 22,018
Net loss per share attributable to common shareholders:    
Basic and diluted $ 0.51 $ 0.48
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 52,564,628 45,649,065
Research And Development Revenue | Other    
Total revenue $ 2,983 $ 1,467
Research And Development Revenue | Related Party    
Total revenue 237 333
Grant    
Total revenue $ 0 $ 2,341